Author:
Rubenstein Marvin,Hollowell Courtney M. P.,Guinan Patrick
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology,General Medicine
Reference26 articles.
1. Mu Z, Hachem P, Pollack A. Antisense bcl-2 sensitizes prostate cancer cells to radiation. Prostate. 2005;65:331–40.
2. Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-wittke U, Gleave M. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting bcl-2 and bcl-xL genes. BJU Int. 2006;97:1300–8.
3. Rubenstein M, Hollowell CMP, Guinan P. Inhibition of bcl-2 by antisense oligonucleotides is followed by a compensatory suppression of caspase-3 in LNCaP cells. Eur J Clin Med Oncol. 2011;3:1–6.
4. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and prostate cancer. Genes Cancer. 2010;1:617–28.
5. London CA, Sekhon HS, Arora V, Stein DA, Iverson PL, Devi GR. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther. 2010;10:823–32.